Abstract Tumor profiling (TP) is primarily used to identify driver mutations within a tumor for treatment purposes, but it may also identify germline mutations. Current involvement of cancer genetic counselors (GCs) in the TP process is not clear. Members of the National Society of Genetic Counselors Cancer Special Interest Group were invited to participate in a confidential, web-based survey to characterize current practices and attitudes related to the use of TP. Of 105 useable responses, 86.7% of GCs reported their institutions were using TP, although only 6.7% did this routinely. Although 63.7% reported personal involvement in the process, largely with result interpretation and follow-up germline testing, 69.7% reported seeing fewer than 5 patients for this reason and 97.9% desired further education on this topic. Work and regional setting were not predictors of involvement with TP; however, GCs in the academic setting were less aware of who obtains consent (p = 0.001). GCs reported they were not often utilized as a resource regarding TP. Overall, GCs believed TP is beneficial in identifying hereditary cancer syndromes, although most reported finding a germline mutation in <10% of cases. This study provides a snapshot of current GC involvement with TP, and documents the desire by GCs for additional education on tumor profiling.
Introduction
Next-generation sequencing (NGS) in oncology has largely been used to identify germline DNA mutations within cancer predisposition genes in patients considered to be at high risk for hereditary cancer (Meiser et al. 2008) . As the knowledge and technology surrounding cancer genetics has increased at an exponential rate, tumor profiling (also known as tumor genomic profiling), a newer use of NGS technology, has shown emerging clinical utility for identification of driver mutations (Dancey et al. 2012; Varga et al. 2015) . Driver mutations are defined as the molecular alterations within a tumor responsible for initiation and maintenance of cancer (Stratton et al. 2009 ). The use of tumor profiling is still in its infancy, but is becoming a more common practice in oncology. The identification of driver mutations in tumors allows for treatment optimization, also known as precision medicine (Mirnezami et al. 2012) . Although the intent of the testing is to provide information about the genetic changes in the DNA of the tumor to suggest treatment strategies, there may be incidental findings of mutations that could be related to an underlying hereditary cancer syndrome (Johnston et al. 2012; Kou et al. 2016) . While genetic counselors have traditionally been involved in NGS testing for germline mutations associated with hereditary cancer, incidental findings of possible germline mutations necessitates their involvement with tumor profiling (Jain et al. 2016; Robson et al. 2015) . A patient may not know they are at risk for hereditary cancer or a hereditary cancer syndrome, so they may be referred to a genetic counselor to discuss findings and consider germline testing (Everett et al. 2014) . As the use of tumor profiling increases, more patients may be referred to genetic counselors to discuss their test results and the implications of a germline mutation.
Previous studies have explored the emerging roles of genetic counselors in precision oncology (Everett et al. 2014) , suggesting the implementation of guidelines concerning genetic testing in the cancer setting (Lolkema et al. 2013; Meiser et al. 2008) and postulating who should discuss treatment-targeted testing with patients, i.e., the oncologist versus a cancer genetic counselor (Douma et al. 2015) . Additional research has shown the increased prevalence of tumor profiling for cancer treatment optimization (Dancey et al. 2012; Mirnezami et al. 2012; Varga et al. 2015) and have discussed the possibility of incidental findings (Everett et al. 2014; Johnston et al. 2012; Kou et al. 2016; Robson et al. 2015) . While guidelines have been recommended by the American Society of Clinical Oncology (ASCO) regarding germline implications of somatic testing (Robson et al. 2015) , there are no established standards of practice for tumor-based NGS, nor is there an accurate understanding of cancer genetic counselors' formal education and involvement in the process. Boland et al. (2015) assessed genetic counselors' knowledge of germline and tumorbased NGS testing, noting that less than half of genetic counselors considered their involvement in tumor-based NGS testing to be necessary. Genetic counselors expressed the need for additional education, leading to the suggestion of a reassessment of their knowledge after they have more exposure to this practice and receive formal education (Boland et al. 2015) . However, there is no previously published information on the current involvement of cancer genetic counselors with regard to tumor profiling.
The objectives of this research were to: (1) assess genetic counselors' awareness of the tumor profiling process within their institution, (2) assess genetic counselors' involvement in the tumor profiling process, (3) identify work setting and regional differences in tumor profiling practices, and (4) explore genetic counselors' attitudes related to tumor profiling.
Methods

Participants and Procedures
All participants were cancer genetic counselors who were recruited through the National Society of Genetic Counselors' (NSGC) Cancer Special Interest Group (SIG). An invitation to participate in a web-based survey titled BTumor gene expression profiling^was posted to the Cancer SIG Discussion Forum and sent via email to the Cancer SIG Listserv through the NSGC Student Research Survey Program. The invitation provided an introduction to the survey, which was described as an anonymous survey to investigate cancer genetic counselors' current practices and attitudes related to the use of tumor profiling. Members received the initial invitation and a follow-up reminder two weeks later. The survey was available between 12/9/2015 and 1/22/2016. Participation in this survey was voluntary. Only board-certified or board-eligible genetic counselors involved in cancer genetics activities (clinical or research) and direct patient care were eligible to participate in this study. Participants did not receive reimbursement or payment for their participation. This study and all protocols were approved by the St. Vincent Health and Indiana University School of Medicine Institutional Review Boards (#R20150119, #1510317348, respectively).
Instrumentation
A quantitative survey assessed participants' degree of involvement with tumor profiling as well as their attitudes toward the practice. Previously validated survey questions were adapted from the 2014 NSGC Professional Status Survey (PSS) (NSGC 2014b) as well as from previous research (Boland et al. 2015) . The final 25-item survey assessed participants' demographic information, their institution's use of tumor profiling, personal involvement in the tumor profiling process, preparedness to participate in the process, attitudes towards tumor profiling, and desire for education regarding the use of tumor profiling. Consistent with previous research, the attitude statements involved the use of a four-point Likert scale (strongly agree to strongly disagree). The survey was piloted among a small group of genetic professionals within St. Vincent Health and Indiana University. The final survey took approximately 15 min to complete online. For this study, tumor profiling was defined as the process of testing a tumor with NGS for the presence of driver mutations to identify potential treatments.
Data Analysis
Data analysis included descriptive statistics and univariate associations with Fisher's Exact tests and Pearson's Chisquared tests. Demographics and general tumor profiling usage characteristics were analyzed and reported descriptively. Fisher's Exact tests and Pearson Chi-squared test were also used to compare the type of direct patient care to personal involvement in tumor profiling, as well as work and regional settings to tumor profiling usage characteristics. Additional sub analyses were performed using these tests, but were limited to only those involved with tumor profiling. All analyses were conducted using IBM SPSS 23.0 (IBM SPSS 2015) and the significance level was set at p < 0.05.
Results
Respondent Profile
A total of 119 individuals responded to the survey. Fourteen surveys were excluded based on eligibility criteria, resulting in 105 qualified responses from cancer genetic counselors who provide direct patient care. Based on the number of NSGC Cancer SIG members in September 2015 (n = 835), the response rate was 14.3% (119/835). The majority of qualified respondents (95/105, 90.5%) reported spending >50% of their time in cancer genetics activities, with 86.7% (91/105) providing direct patient care on a clinical basis only (Table 1) . Of these respondents, 96.8% (93/96) were from the United States and 3.2% (3/96) were from Canada (data not shown). The majority of respondents (49/95, 51.6%) worked in a public or private hospital/medical center (Table 1) . Though all regions were represented, the most prevalent were Region 4 (35/95, 36.8%) and Region 2 (28/95, 29.5%). The work setting and region responses are similar to those reported in the 2014 NSGC PSS Cancer Genetics Analysis (NSGC 2014a).
Genetic Counselors' Awareness of the Tumor Profiling Process within their Institution
The majority of genetic counselors (91/105, 86.7%) reported that their institution is ordering tumor profiling (Table 1) . Of those, 48.9% (44/90) indicated tumor profiling has been utilized in their institutions for greater than 1 year, but 38.9% (35/ 90) were unaware of how long it has been used. Most (66/90, 73.3%) answered that it is not part of general practice for all patients. Respondents indicated that the professional primarily involved in informed consent was the medical oncologist (61/ 89, 68.5%), although 22.5% (20/89) of respondents indicated not knowing who was involved in informed consent. Additionally, the majority (55/88, 62.5%) of genetic counselors reported that they are not utilized as a resource for other healthcare providers regarding tumor profiling.
Genetic Counselors' Involvement in the Tumor Profiling Process
Over half of genetic counselors (65/102, 63.7%) reported personal involvement with tumor profiling in some capacity (Table 1) . Of those, they were most often involved with results interpretation (45/65, 69.2%) and follow-up testing (50/65, 76.9%) (Fig. 1 ). Fifty-five percent (36/65) have provided genetic counseling when the main reason for referral was to discuss tumor profiling test results, although most (25/36, 69.4%) have done so less than 5 times (Table 2) . Nearly all genetic counselors reported that, in most of those cases, the patient was aware of their tumor profiling result before the referral was made (34/36, 94.4%) and that the number of referrals for patients with tumor profiling results has increased (14/36, 38.9%) or stayed the same (19/36, 52.8%) over the past 6 months.
All respondents (65/65, 100%) indicated that tumor profiling has come up less than 25% of the time in a genetic counseling session when it was not the main reason for the referral. In those cases, 72.3% (47/65) of patients were aware of their results before the session. In the experience of most genetic counselors (50/65, 76.9%), tumor profiling results have infrequently (<10% of the time) led to the identification of a hereditary cancer syndrome.
Work Setting and Regional Differences in Tumor Profiling Practices
Work setting and region were not predictors of involvement with tumor profiling (data not shown). The only statistically significant correlation of this study revealed that genetic counselors personally involved with tumor profiling within a university medical center were less aware of the primary professional involved in the informed consent process than genetic counselors within all other work settings (p = 0.001) ( Table 3) .
Genetic Counselors' Attitudes Related to Tumor Profiling
All respondents were asked about their attitudes concerning tumor profiling. There were no differences in attitudes about tumor profiling regardless of level of personal involvement with tumor profiling (data not shown). Over half (63/97, 64.9%) agreed that it is important that genetic counselors be involved in reviewing tumor profiling results (Table 4) . A greater proportion (71/97, 73.2%) agreed that tumor profiling is beneficial in identifying individuals with a hereditary cancer syndrome. However, most respondents disagreed that it is important for genetic counselors to be involved in the informed consent process for tumor profile testing (62/97, 63.9%) or to know about the treatment options based on test results (59/97, 60.8%).
A large portion of respondents (41/97, 42.3%) believed that genetic counseling for tumor profiling results will become a routine part of patient practice within 2-5 years (Table 4) . Overall, only 16.5% (16/97) of genetic counselors felt their institution was completely prepared to handle tumor profiling results, and only 5.2% (5/97) felt they were personally completely prepared. The vast majority of respondents (95/ 97, 97.9%) expressed interest in attending an educational session on tumor profiling.
Discussion
This research provides a snapshot of cancer genetic counselors' current involvement with, and attitudes regarding, tumor profiling. The data demonstrate there is limited use of genetic counselors' expertise by other healthcare providers in tumor profiling, the roles of cancer genetic counselors in the process of tumor profiling are still emerging, and genetic counselors desire additional education on tumor profiling.
Incorporation of tumor profiling into clinical oncology is illustrated by cancer genetic counselors' high awareness of its use within their institution. The majority of respondents' institutions have ordered tumor profiling, with nearly half having utilized the testing for over one year. While this Although there is no published data to provide an expectation of how often a patient will be identified as a potential candidate for germline testing, and respondents were not asked to quantify the number of tumors sequenced at their institution, this level of participation does seem low. This is particularly concerning due to the potential of incidental findings related to hereditary cancer syndromes. Healthcare providers implementing tumor profiling should be aware of the potential for incidental findings and include genetic counselors in the process when appropriate (Everett et al. 2014; Jain et al. 2016) . These findings suggest an opportunity for genetic counselor engagement with oncology GC Genetic Counselor, TP Tumor Profiling healthcare providers to educate them on the possible implications of tumor-based testing and the ways genetic counselors can contribute to the tumor profiling process. Cancer genetic counselors' participation in the tumor profiling process was greatest in the roles of results interpretation and follow-up germline testing, but they did not engage as often in obtaining informed consent and results disclosure. Additionally, in contrast to respondents' heightened awareness of the use of tumor profiling, awareness of who obtains informed consent was lacking among genetic counselors, especially among those in an academic setting. It is unclear why genetic counselors working in this setting were less likely to know who is involved in the informed consent process for tumor profiling, and more study is needed to determine the relevance of this finding.
The lack of involvement and overall lack of awareness of who obtains informed consent raises the question of whether or not patients are educated on the benefits, risks, and limitations of this testing. ASCO guidelines recommend informed consent regarding the implications of germline mutations for all patients undergoing tumor profiling (Robson et al. 2015) . Healthcare providers should inform their patients that incidental findings of germline mutations are possible and that the impact of such findings expand beyond treatment of the current cancer, i.e., implications for family members and potential need for other types of cancer screening (Jain et al. 2016; Lolkema et al. 2013) . Genetic counselors are well-suited to assist with this role or at least provide resources and information to those who are involved in the informed consent process. Genetic counselors can also provide awareness to their counterparts of which situations warrant a referral to genetic counseling for further discussion on germline testing. These practices will promote the expertise and use of genetic counselors to other healthcare providers and contribute to a better patient experience. The roles of cancer genetic counselors in tumor profiling practices are clearly still emerging, and more study is necessary to help define and establish practice guidelines.
Respondent attitudes regarding tumor profiling may provide insight into the current roles of cancer genetic counselors in the tumor profiling process. Most cancer genetic counselors did not feel that their involvement in informed consent or having knowledge about treatment options is necessary. However, they did believe that tumor profiling is beneficial in identifying hereditary cancer syndromes and their involvement is warranted in reviewing these results. These attitudes are present despite the finding that genetic counselors confirmed a hereditary cancer syndrome in less than 10% of cases when a patient was referred due to an abnormal tumor profiling result. This identification rate may seem low, but genetic counselors' use of traditional germline testing has a similar likelihood of a positive result (e.g., the National Comprehensive Cancer Network guidelines for Hereditary Breast and Ovarian Cancer syndrome recommend germline testing for every woman diagnosed with breast cancer under age 50, regardless of family history, due to the identification of a clinically actionable BRCA mutation in 9.5% of the population studied by Weitzel et al. (2007) ) (NCCN 2016) .
Only 5.2% of genetic counselors felt they personally are completely prepared to handle tumor profiling result cases, which may in part be a result of genetic counselors' current lack of knowledge of tumor-based NGS testing and their limited involvement in such cases (Boland et al. 2015) . Moreover, the majority of genetic counselors felt their institutions are not completely prepared to offer tumor profiling for clinical use. These findings likely explain the overwhelming majority of genetic counselors indicating a desire for education on tumor profiling. To foster a more thorough understanding of tumor profiling, continuing education could be offered via online webinars or courses at the annual NSGC education conference. Genetic counseling programs could also include this topic as part of coursework and clinical rotations. Further exploration is needed to fully address this desire and meet the educational needs of genetic counselors.
If tumor profiling continues its expansion and becomes a routine part of patient care in the anticipated 2-5 year time frame, it will be imperative that cancer genetic counselors understand the core purpose of tumor-based testing and become prepared to incorporate genetic counseling for incidental tumor profiling results into their practice. While genetic counselors may not need to know specific treatment plans derived from tumor profiling results, they should be knowledgeable of the fact that the identification of driver mutations guides precision medicine (Mirnezami et al. 2012) . Education, and therefore greater comfort in knowledge of how tumor profiling drives precision oncology, may allow for greater participation in patient care with other healthcare providers. This could potentially take the shape of attending molecular tumor boards, monitoring test use within an institution, creating educational materials for patients to explain the difference between somatic and germline testing, or being utilized as an expert resource (Jain et al. 2016) . By facilitating communication and developing educational tools related to tumor profiling, genetic counselors may enhance their status as experts within cancer genetics and the rapidly evolving practice of precision medicine.
Study Limitations
While our findings regarding genetic counselors' involvement in tumor profiling are enlightening, several limitations of our study should be considered. Although we had adequate power to analyze our research questions, we had a relatively small sample size. This could have been due to a low (14.3%) response rate, which may indicate bias based on the possibility that genetic counselors involved in tumor profiling were more likely to participate because of their interest in the topic. The results of this research represent genetic counselors' involvement in the tumor profiling process at the time of data collection and present a snapshot of current practices. Because limited research exists on the role of genetic counselors with regard to tumor profiling, our findings cannot be compared with previous data. Additionally, while we used validated scales and measures, personal interpretation of the scalebased attitudes questions and undefined terms (such as describing results as Babnormal^) cannot be accounted for in this type of study. Our survey also collected limited demographic information, making it unclear if a representative sampling of genetic counselors based on age, sex, and years of experience was captured and if differences could be identified between demographic groups. Finally, based on our recruiting strategy, it is conceivable that multiple genetic counselors from the same institution may have responded to the survey, which could potentially skew the data. Some of these limitations could be avoided in the future by incorporating a longitudinal design to accommodate for more indepth assessments of demographics and specific institutional information as well as insight to how these practices and attitudes change over time.
Practice Implications
Tumor profiling is an area of oncology that will allow an extension of genetic counselors' skills and expansion of their practice beyond traditional germline testing. As the need for genetic expertise with tumor profiling increases, cancer genetic counselors must seize the opportunity to define their role in precision oncology and take ownership of the elements which fall within their scope of practice. Consistent with previous publications, the results of this study identify a call to action for development of educational opportunities for genetic counselors regarding tumor profiling, establishment of practice guidelines to define genetic counselors' roles in the tumor profiling process, and engagement with oncology healthcare providers in the pursuit of better outcomes (Boland et al. 2015; Robson et al. 2015; Jain et al. 2016) .
By facilitating discussions among genetic counselors and providing opportunities for education, the NSGC may be a great resource to foster understanding and define best practices. A collaborative approach between cancer genetic counselors and other healthcare providers should also be considered to fill educational gaps and streamline the tumor profiling process, especially given the limited genetic counselor workforce. This systemic approach may ultimately lead to more effective care of patients and additional family members with, or at risk for, cancer.
Future Research Recommendations
The results of this research may be used as a benchmark for the involvement, awareness and educational needs of genetic counselors in the tumor profiling process. Future quantitative and qualitative research objectives might include assessing the role of genetic counselors in non-clinical settings such as laboratories, developing guidelines regarding the genetic counselor's role in tumor profiling, and assessing changes in awareness, involvement, and attitudes regarding tumor profiling. Additional quantitative studies as well as qualitative interviews with genetic counselors who have the most experience with tumor profiling could be used to achieve these future objectives.
